Optimise Product Potential
WILEX intends to enter into strategic co-development and commercialisation partnerships.
The antibody RENCAREX® was in a pivotal Phase III trial in the adjuvant treatment of non-metastatic renal cell carcinoma (RCC). In October 2012 WILEX announced that RENCAREX® did not meet its primary endpoint and showed no improvement in median DFS in the Phase III registration trial. The trial therefore was terminated.
- WILEX has partnered RENCAREX® for co-development and commercialisation in certain countries of South Europe (Spain, Italy, Portugal, Greece, and Andorra) with the Spanish pharmaceutical company Laboratorios del Dr. Esteve, Barcelona, Spain (Press Release).
REDECTANE® (INN: 124I-Girentuximab) is a radiolabeled form of the monoclonal antibody Girentuximab, which binds to the Carbonic Anhydrase-9 (CAIX) antigen, expressed on the surface of cancer cells of the clear-cell phenotype. It has been shown that REDECTANE® with positron emission tomography (PET) and computer tomography (CT) is clearly superior to the use of diagnostic CT alone in diagnosing clear cell renal cell carcinomas.
MESUPRON® belongs to the uPA programme of WILEX AG. According to the Company the uPA programme is a promising new non-cytotoxic approach in cancer therapy to specifically block tumour metastasis and primary tumour growth in solid cancers. The drug candidate MESUPRON® is being developed for anti-metastatic treatment in a wide variety of solid tumour types.
WILEX holds the worldwide commercialisation rights of its uPA programme, including the following development candidates:
- Oral uPA and serine protease inhibitor MESUPRON® (in phase II studies in patients with pancreatic or breast cancer)
- Several other compounds targeting components of the uPA system (Research)
At the end of June 2014, WILEX entered into a second licensing and development partnership with the Israeli company RedHill Biopharma Ltd. covering all regions with the exception of Greater China. (Press Release)